Literature DB >> 12084010

TACE inhibition: a new approach to treating inflammation.

Sheila A Doggrell1.   

Abstract

Clinical trials showing the benefits of reducing the effects of TNF- alpha in rheumatoid arthritis have highlighted the key role of the cytokine TNF- alpha in this inflammatory condition. A new approach to reducing the effects of TNF- alpha is to decrease its synthesis by inhibiting TNF- alpha converting enzyme with GW3333. In rat models of arthritis, GW3333 has some beneficial effects. Further longer-term studies of GW3333 in animal models are required to determine whether its benefit is maintained. TACE inhibition may represent a new approach to treating inflammation.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12084010     DOI： 10.1517/13543784.11.7.1003

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


  6 in total

Review 1.  Novel host response therapeutic approaches to treat periodontal diseases.

Authors:  Keith L Kirkwood; Joni A Cirelli; Jill E Rogers; William V Giannobile
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

2.  Improving Donor Livers by Inhibiting TNF-α Production.

Authors:  Christopher P Zetzmann; O Rama Swamy; George E Loss; Humberto Bohorquez; Ari J Cohen
Journal:  Ochsner J       Date:  2010

3.  Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice.

Authors:  Vincent E de Meijer; Deanna Y Sverdlov; Yury Popov; Hau D Le; Jonathan A Meisel; Vânia Nosé; Detlef Schuppan; Mark Puder
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

4.  Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells.

Authors:  Aramati B M Reddy; Kota V Ramana; Sanjay Srivastava; Aruni Bhatnagar; Satish K Srivastava
Journal:  Endocrinology       Date:  2008-09-04       Impact factor: 4.736

5.  Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice.

Authors:  Vincent E de Meijer; Hau D Le; Jonathan A Meisel; Anisha K Sharma; Yury Popov; Mark Puder
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

6.  Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.

Authors:  Halka Buryova; Karel Chalupsky; Olga Zbodakova; Ivan Kanchev; Marketa Jirouskova; Martin Gregor; Radislav Sedlacek
Journal:  BMC Gastroenterol       Date:  2013-10-30       Impact factor: 3.067
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.